TABLE 1.
Baseline characteristics of study participants (PPS analysis)1
| Placebo (n = 46) | OLL2712 (n = 46) | |
|---|---|---|
| Anthropometrics | ||
| Age, y | 44.7 ± 8.2 | 45.5 ± 10.7 |
| Gender, male/female, n | 33/13 | 30/16 |
| Weight, kg | 77.3 ± 8.9 | 74.4 ± 8.2 |
| Height, cm | 168 ± 9 | 165 ± 8 |
| BMI, kg/m2 | 27.5 ± 1.4 | 27.4 ± 1.3 |
| Body fat, % | 32.1 ± 6.1 | 32.1 ± 5.4 |
| Waist circumference, cm | 94.3 ± 4.7 | 93.3 ± 4.1 |
| Hip circumference, cm | 100.2 ± 3.6 | 99.2 ± 3.9 |
| Waist-to-hip ratio | 0.942 ± 0.04 | 0.941 ± 0.04 |
| Abdominal fat area, cm2 | ||
| Total | 337 ± 60 | 325 ± 56 |
| Visceral | 107 ± 21 | 102 ± 16 |
| Subcutaneous | 230 ± 55 | 223 ± 57 |
| Glycemic control | ||
| FPG, mg/dL | 83.6 ± 6.6 | 86.3 ± 6.4 |
| Whole blood HbA1c, % | 5.45 ± 0.31 | 5.48 ± 023 |
| Fasting serum insulin, mU/L | 6.83 ± 2.38 | 7.31 ± 3.02 |
| HOMA-IR | 1.41 ± 0.51 | 1.57 ± 0.71 |
| Serum ketone bodies, µmol/L | 76.6 ± 75.3 | 89.4 ± 88.6 |
| Cardiovascular disease risk factors | ||
| Systolic blood pressure, mmHg | 120 ± 16 | 119 ± 12 |
| Diastolic blood pressure, mmHg | 71.4 ± 10.9 | 69.9 ± 8.4 |
| Heart rate, bpm | 71.5 ± 11.1 | 74.6 ± 9.6 |
| Serum total cholesterol, mg/dL | 216 ± 34 | 204 ± 37 |
| Serum LDL cholesterol, mg/dL | 134 ± 28 | 126 ± 32 |
| Serum HDL cholesterol, mg/dL | 48.3 ± 10.4 | 49.4 ± 9.1 |
| Serum triglycerides, mg/dL | 142 ± 171 | 122 ± 62 |
| Chronic inflammation markers | ||
| Serum IL-6, pg/mL | 0.442 ± 0.857 | 0.870 ± 1.518 |
| Serum IL-8, pg/mL | 6.03 ± 2.43 | 6.37 ± 2.10 |
| Serum MCP-1, pg/mL | 25.2 ± 9.8 | 34.2 ± 14.3 |
| Serum TNF-α, pg/mL | 10.1 ± 4.1 | 11.4 ± 3.8 |
| Serum hs-CRP, mg/dL | 0.0659 ± 0.0519 | 0.0712 ± 0.0736 |
| Serum adiponectin, mg/mL | 4.59 ± 1.81 | 4.37 ± 1.63 |
1
Values are means ± SD or n, n = 46 in each group.
FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; hs-CRP, high-sensitivity C-reactive protein; MCP-1, monocyte chemotactic protein-1; PPS, per-protocol set.